Sub-topics: Biomarkers of biological age vs. chronological age, NAD+ boosters, mTOR inhibitors (e.g., rapamycin analogs), clinical trial design in longevity.

Description: Explores the transition of geroscience from bench to bedside, evaluating emerging pharmaceutical compounds aimed at modulating aging processes to prevent or delay age-related chronic diseases simultaneously.